242 related articles for article (PubMed ID: 11237061)
21. Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia.
Gameiro P; Moreira I; Yetgin S; Papaioannou M; Potter MN; Prentice HG; Hoffbrand AV; Foroni L
Br J Haematol; 2002 Dec; 119(3):685-96. PubMed ID: 12437645
[TBL] [Abstract][Full Text] [Related]
22. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
23. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
25. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
27. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
[TBL] [Abstract][Full Text] [Related]
30. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
[TBL] [Abstract][Full Text] [Related]
31. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
32. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
34. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
[TBL] [Abstract][Full Text] [Related]
35. Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia.
Bassan R; Intermesoli T; Scattolin A; Viero P; Maino E; Sancetta R; Carobolante F; Gianni F; Stefanoni P; Tosi M; Spinelli O; Rambaldi A
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S2-S9. PubMed ID: 28760298
[TBL] [Abstract][Full Text] [Related]
36. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
37. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
38. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
39. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
[TBL] [Abstract][Full Text] [Related]
40. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]